Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $24.26 USD
Change Today -0.24 / -0.98%
Volume 221.0K
XLRN On Other Exchanges
As of 8:10 PM 10/8/15 All times are local (Market data is delayed by at least 15 minutes).

acceleron pharma inc (XLRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/8/14 - $48.50
52 Week Low
08/24/15 - $20.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACCELERON PHARMA INC (XLRN)

Related News

No related news articles were found.

acceleron pharma inc (XLRN) Related Businessweek News

No Related Businessweek News Found

acceleron pharma inc (XLRN) Details

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. The company is developing luspatercept and sotatercept therapeutic candidates, which are in Phase 3 clinical trials used to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes. The sotatercept therapeutic candidate is also used to increase bone mineral density; and to treat the final stage of chronic kidney disease and end-stage renal disease. It is also developing dalantercept therapeutic candidate to treat renal cell carcinoma and hepatocellular carcinoma; and ACE-083 that is in Phase 1 clinical trial used to promote muscle growth and function in specific treated muscle groups. It has collaboration, license, and option agreement with Celgene Corporation. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.

83 Employees
Last Reported Date: 03/2/15
Founded in 2003

acceleron pharma inc (XLRN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $460.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $325.0K
Chief Operating Officer and Executive Vice Pr...
Total Annual Compensation: $335.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $392.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $335.0K
Compensation as of Fiscal Year 2014.

acceleron pharma inc (XLRN) Key Developments

Acceleron Pharma Inc. Presents Preclinical Data for ACE-083 and ACE-2494 At the 20th International Annual Congress of the World Muscle Society

Acceleron Pharma Inc. reported results from preclinical studies of ACE-083, a locally-acting muscle therapeutic, and from ACE-2494, a systemic muscle therapeutic and a new Acceleron program first introduced. Data from both programs were presented at the 20th International Annual Congress of the World Muscle Society (WMS) held in Brighton, United Kingdom. ACE-2494 is a ligand trap that inhibits the key negative regulators of skeletal muscle, thereby systemically increasing skeletal muscle mass and strength. In mice, ACE-2494 generated dose dependent increases in muscle mass at a magnitude comparable to the powerful effects of soluble ActRIIB fusion proteins. After 4 weeks of treatment, ACE-2494 (10 mg/kg twice weekly) generated substantial increases in muscle mass: 41% (rectus femoris), 53% (gastrocnemius), and 87% (pectoralis). ACE-2494 is engineered to achieve muscle enhancement by selectively inhibiting negative regulators of skeletal muscle, while avoiding the effects on regulators of the vasculature that have been observed with soluble ActRIIB fusion proteins. ACE-083 is a locally-acting therapeutic candidate that has been designed to increase skeletal muscle mass and strength selectively in only the muscles into which the drug is administered. In this preclinical study, ACE-083 demonstrated increases in both muscle mass and strength. In mice, ACE-083 was administered by injection into the right tibialis anterior (TA) muscle twice per week for 3 weeks. ACE-083 produced significant increases in muscle mass of roughly 75% in the injected muscle with no observed effect on either the uninjected contralateral muscle or on whole body mass. These results are consistent with a local effect only in the injected muscle. Increases in muscle mass were associated with a significant increase in muscle force and power of roughly 40%. Changes in muscle strength were due to larger fiber size rather than altering the kinetic properties of the muscle.

Acceleron Pharma, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 09:40 AM

Acceleron Pharma, Inc. Presents at Leerink Partners 4th Annual Rare Disease Roundtable, Sep-30-2015 09:40 AM. Venue: Le Parker Meridian, New York, New York, United States. Speakers: Steven D. Ertel, Chief Operating Officer and Executive Vice President.

Acceleron Pharma, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-10-2015

Acceleron Pharma, Inc. Presents at Citi 10th Annual Biotech Conference, Sep-10-2015 . Venue: Mandarin Oriental New York, 80 Columbus Circle, New York, NY 10023, United States.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XLRN:US $24.26 USD 0.00

XLRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XLRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation XLRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 46.5x
Price/Book 5.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 40.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCELERON PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at